Natera received FDA designation and Natera stock trades at EUR 356.60

Published on 10/13/2026 at 11:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The FDA reviewed data across 12 cancer types on October 9, 2026. Natera stock trades at EUR 356.60 on October 13, 2026 with Q2 revenue at USD 752.75 million.

Natera received FDA Breakthrough Device designation for its multi-cancer early detection assay on October 9, 2026.
Second-quarter 2026 revenue reached USD 752.75 million, up 37.70 percent year over year.
Natera stock was trading at EUR 356.60 at Lang & Schwarz on October 13, 2026 at 11:35 a.m. CEST.
Morgan Stanley raised its Natera price target from USD 355.00 to USD 435.00 on October 12, 2026.

NTRA, US6323071042, Illustration mit AI erstellt.

Natera (ISIN US6323071042) received FDA Breakthrough Device designation for its multi-cancer early detection assay on October 9, 2026, while Natera stock was trading at EUR 356.60 at Lang & Schwarz on October 13, 2026 at 11:35 a.m. CEST. Natera said the FDA assessed data covering 12 cancer types.

FDA designation expands oncology optionality

The designation gives Natera access to closer interaction with FDA experts during development and review. It is a regulatory milestone rather than marketing authorization, leaving clinical validation and future submissions as the next steps for the blood-based assay.

The announcement follows two October research developments. On October 5, Natera and Alliance Foundation Trials launched a randomized phase III breast cancer trial using Signatera-guided treatment, with four-year distant recurrence-free survival as the primary endpoint, according to StockTitan.

Revenue growth supports the valuation

In the second quarter of 2026, revenue reached USD 752.75 million, up 37.70 percent from the same quarter a year earlier. Natera also reported a GAAP net loss of USD 66.97 million, equal to diluted earnings per share of minus USD 0.47, according to MarketBeat.

On October 12, 2026, Markets Insider reported that Morgan Stanley raised its price target from USD 355.00 to USD 435.00 and maintained an Overweight rating. The target revision puts the analyst view above the current US quotation of USD 397.77 dated October 12, 2026, although that primary-market value is separate from the euro reference price.

Three dated operating milestones

On October 5, 2026, the breast cancer trial began with Signatera-guided treatment. On October 7, 2026, Natera announced enrollment of the first patients in a randomized Signatera-guided melanoma study, as Natera reported. The October 9, 2026 FDA designation is the latest milestone and covers data from 12 cancer types.

What does the designation change?

The immediate change is procedural: the MCED program can receive more direct FDA interaction during development. The financial test remains execution, because the second-quarter loss of USD 66.97 million sits alongside rapid revenue expansion and an oncology pipeline that still requires additional evidence.

Stock price and investor context

Natera stock was trading at EUR 356.60 at Lang & Schwarz on October 13, 2026 at 11:35 a.m. CEST. The finance quote for Nasdaq showed a market capitalization of USD 57.0 billion and a 52-week range of USD 170.81 to USD 437.41 as of October 12, 2026.

The further course of trading is shown by the continuously updated real-time quote of Natera stock.